[go: up one dir, main page]

MX2016002720A - Metodo para mejorar la estabilidad del anticuerpo. - Google Patents

Metodo para mejorar la estabilidad del anticuerpo.

Info

Publication number
MX2016002720A
MX2016002720A MX2016002720A MX2016002720A MX2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A
Authority
MX
Mexico
Prior art keywords
asp
antibody
asn
residue
atom
Prior art date
Application number
MX2016002720A
Other languages
English (en)
Inventor
Hubert Kettenberger
Stefan Klostermann
Florian Lipsmeier
Apollon Papadimitriou
Jasmin Sydow-Andersen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016002720A publication Critical patent/MX2016002720A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Computing Systems (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para seleccionar o deseleccionar un anticuerpo que comprende: a) determinar para cada residuo de Asp y Asn en una región de anticuerpo Fv, la flexibilidad conformacional del átomo Ca usando un montaje de modelo de homología, b) determinar para cada residuo de Asp y Asn en una región de anticuerpo Fv, el tamaño del residuo de aminoácido C-terminal al residuo de Asp o Asn, y c) seleccionar un anticuerpo en el que el átomo Ca es conformacionalmente inflexible y/o el residuo de Asp o Asn tiene un residuo de aminoácido C-terminal grande, o deseleccionar un anticuerpo en el que el átomo Ca tiene una flexibilidad conformacional moderada a alta y/o el Asp y Asn tiene un residuo de aminoácido C-terminal pequeño.
MX2016002720A 2013-09-06 2014-09-03 Metodo para mejorar la estabilidad del anticuerpo. MX2016002720A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183389 2013-09-06
EP13184174 2013-09-12
PCT/EP2014/068649 WO2015032776A1 (en) 2013-09-06 2014-09-03 Method for improving antibody stability

Publications (1)

Publication Number Publication Date
MX2016002720A true MX2016002720A (es) 2016-06-08

Family

ID=51485608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002720A MX2016002720A (es) 2013-09-06 2014-09-03 Metodo para mejorar la estabilidad del anticuerpo.

Country Status (10)

Country Link
US (2) US10418126B2 (es)
EP (2) EP3761033A3 (es)
JP (1) JP6580570B2 (es)
KR (1) KR20160052562A (es)
CN (1) CN105518461B (es)
CA (1) CA2918191A1 (es)
DK (1) DK3042205T3 (es)
MX (1) MX2016002720A (es)
RU (1) RU2711719C2 (es)
WO (1) WO2015032776A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN114207728A (zh) * 2019-08-02 2022-03-18 杰南技术公司 通过基于物理的模拟预测聚合物中的侧链降解

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100736A (en) * 1870-03-15 dundeedale
RU2134724C1 (ru) * 1992-08-24 1999-08-20 Ниссин Сокухин Кабусики Кайся Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
EP1793847A2 (en) * 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
US7951918B2 (en) * 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
RU2009137582A (ru) * 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
CA2728829C (en) * 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
JP5990102B2 (ja) * 2009-09-29 2016-09-07 ユニフェルシテイト ヘント ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
KR20160134687A (ko) * 2014-03-21 2016-11-23 에프. 호프만-라 로슈 아게 항체의 생체내 반감기의 시험관내 예측방법
EP3122762A1 (en) * 2014-03-28 2017-02-01 Novozymes A/S Enzyme variants and polynucleotides encoding same
WO2015183710A1 (en) * 2014-05-30 2015-12-03 Novozymes A/S Variants of gh family 11 xylanase and polynucleotides encoding same

Also Published As

Publication number Publication date
US20160275238A1 (en) 2016-09-22
WO2015032776A1 (en) 2015-03-12
US20200066372A1 (en) 2020-02-27
CN105518461B (zh) 2018-04-13
CN105518461A (zh) 2016-04-20
EP3042205A1 (en) 2016-07-13
EP3761033A3 (en) 2021-01-20
CA2918191A1 (en) 2015-03-12
RU2016111352A3 (es) 2018-05-23
EP3042205B1 (en) 2019-12-25
JP2016530288A (ja) 2016-09-29
EP3761033A2 (en) 2021-01-06
KR20160052562A (ko) 2016-05-12
HK1223684A1 (zh) 2017-08-04
RU2016111352A (ru) 2017-10-11
US10418126B2 (en) 2019-09-17
DK3042205T3 (da) 2020-03-02
JP6580570B2 (ja) 2019-09-25
RU2711719C2 (ru) 2020-01-21

Similar Documents

Publication Publication Date Title
PH12018501839A1 (en) St2l antagonists and methods of use
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
TN2014000438A1 (en) Anti-fcrn antibodies
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX2015002873A (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
PH12016500753B1 (en) Antibodies specific to fcrn
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
NZ717399A (en) Antibodies against csf-1r
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
AU2012285875A8 (en) Use of c-Fms antagonists
MX2016002720A (es) Metodo para mejorar la estabilidad del anticuerpo.
MX2016002177A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MX2015015023A (es) Metodo para la determinacion de cobre libre.
UY34564A (es) Utilización en terapéutica de derivados de imidazopiridina
EA201890720A1 (ru) Лечение диабетической периферической нейропатии с применением плацентарных клеток